版次: 头版（v1）
日期: 2025-11-23
主题: 奥司他韦近7天销量上涨率达237%

来源: https://www.baidu.com/s?wd=%E5%A5%A5%E5%8F%B8%E4%BB%96%E9%9F%A6%E8%BF%917%E5%A4%A9%E9%94%80%E9%87%8F%E4%B8%8A%E6%B6%A8%E7%8E%87%E8%BE%BE237%25&sa=fyb_news&rsv_dl=fyb_news

# 奥司他韦近7天销量上涨率达237%

## 摘要
- 截至2025年11月23日，受中国流感季提前到来及流感活动水平显著上升影响，抗流感药物奥司他韦（Oseltamivir）销量激增，部分互联网医药电商平台数据显示其近7天销量上涨率高达237% [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=) [szhk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGU9t8CSX2ikqwrDXr7b_jBMgchcH8glGcq8rZVfZFs_QmBYB0xdV3Emesz5kT9sYQ4iBSy6TPQ0c-MNgBvU9h4z4RaCo5cWWDG5s5hQJMvdyzRb_2vKiFFMAKP2tV7N9lBUp7RVpYn)。
- 本轮流感疫情主要由甲型H3N2亚型病毒引起，公众普遍缺乏免疫基础，导致感染人数增加，尤其5至14岁年龄组儿童感染率较高 [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [bjd](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDKh5ce29Cix9_W-gs3vzboBhfOjZrxzB6RR1Slw0A1gLBXjs3HGox0H7-evqCAtLwr5SfGV1mZMOXZbV_MJtohdwW5DMLcita4etRYPQk5VoAzHb9mcD5YA9PqAO3HEoxELS9n92sXAunG54=)。
- 尽管需求旺盛，奥司他韦的生产企业已24小时不间断生产以保障市场供应，目前线上线下药店储备充足，供应链运转有序 [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=) [udn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGXiq6Lak6ieIc6I2tHqBxJwsNeSHLCSYMmvnmZhbxthlQWXMQdo6Q4kyRA3hvob5VgJra8cTWm6zP-1bMB4a5KgBiAnRmPg09ufby7dgMPF6b8BWdvathFtjhtE25j--J) [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErry8sXUAd_oOkKns0mxl4bB5ocYoRA-CnJi2tNMvsbD3oTsVnxxoBz2-HXabRC0EU636kv0G5F43QN9UdZSLZAgC5xbMaOn0ukQxbrZeX5kPWrHu6zzbDXD86EER_df94YstBgIo=)。
- 2025年被视为“国产流感创新药元年”，多款新型流感药物如玛舒拉沙韦片、昂拉地韦片和玛硒洛沙韦片已获批上市，加剧了市场竞争，但奥司他韦仍占据重要的市场份额，尤其在儿童用药领域 [chinapress](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKz0yD5U75kXEHbmM1U3RRAZogBdZ_JFdH5JIAhPVeoNKZwllmF34uSXshpn88JwEWrmbq07X02YPDS0WDCGGVFs0YkZ3OkaTTa4zl6WWrFNyqn7gGnZ9WRtsbJnsVJqJ7Dhm6egjc0rQjkxFSCB-_pkqOl_1LmIGazKAosvYHgXIj6L4atZHUhJW8EzRvpfI_mYAylpkRtUNOkc7gvF56NKfgCHeisCx_ssSdc8bvfvGIaxdRvJNCzChfaCvZ3GkuD9EmgtO-KB5UvVBQaXWTPkOrp_Ukfarr87nBNTNBhbPl-4q0eHbkWjhfZ9-KSuj1EHkhseqtNgjR1AGxqtQjwBgyQVQcoh4=) [udn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGXiq6Lak6ieIc6I2tHqBxJwsNeSHLCSYMmvnmZhbxthlQWXMQdo6Q4kyRA3hvob5VgJra8cTWm6zP-1bMB4a5KgBiAnRmPg09ufby7dgMPF6b8BWdvathFtjhtE25j--J) [sina](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF59Mqe_JVGW3LjrAFHM8_lMAd3xdrflszQCFOfl0-s1cYAS4JK8JD0vRg4Bke7-aIUgY6N9EoWx7F20nMTH-Sm7DpqTCdUy8j0i1SWjN2phXxb6ppFQAbH_HJ07YYgbfUQHsCTi4iIgWzqht-xDdWWrsSbm5k_yF8=)。
- 受国家药品集中带量采购政策影响，奥司他韦仿制药价格大幅下降，最低中标价已不足1元/粒，但原研药达菲价格仍相对较高 [cna](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXzQFl-6jRkVYISfWKCZDg6Q4Jj32PzuxXO3QqU7X9sZhei3zDnu-gOx13uQq2pukxA0V43uwJzLTz9OKQBC9g97-8c3UrmYk3Z-BuN7fgVXB36XoLisMBCqS56fvitXKzJySY3KADf2JlX7c=) [qq](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKXHKAHQ10ou-5TjNMkoZoR7QK4rv0cyniOvVdkTp-qrpHL5FoqKG2i_nKxBLTr9mhAsqJVsTfR9lJihXTGjWD8i4K5C4O7LpR3A-5DkFLl-noFToJCAYN63F0131A0Q3zn8Bfft8=) [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErry8sXUAd_oOkKns0mxl4bB5ocYoRA-CnJi2tNMvsbD3oTsVnxxoBz2-HXabRC0EU636kv0G5F43QN9UdZSLZAgC5xbMaOn0ukQxbrZeX5kPWrHu6zzbDXD86EER_df94YstBgIo=)。

## 背景
进入2025年11月，中国多地流感活动水平显著上升，标志着全国已全面进入流感流行季。中国疾病预防控制中心数据显示，绝大多数省份已进入流感流行期，且流感活动水平持续上升，预计今年秋冬季的流感疫情高峰可能出现在12月中下旬和2026年1月初，较往年有所提前 [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=) [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [people](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFRQ0ySItgn4ljgI5TkhJIQNJfmF9_KACy9mLSZcVYL8u7Wcez2DUhXpXS4qIT0AmBLV47KiB4npMue0vE6vR-MmCNe-KWyiI-ke0wlw3Af2yGhYtZUvhNR2ONuTzDFMBYoQSvqC3zikz6c4jVwIH0WUUs7VTkf1ac=)。

本流行季主要流行的流感病毒株是甲型H3N2亚型，同时存在少量甲型H1N1和乙型流感病毒共同流行 [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=) [udn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGXiq6Lak6ieIc6I2tHqBxJwsNeSHLCSYMmvnmZhbxthlQWXMQdo6Q4kyRA3hvob5VgJra8cTWm6zP-1bMB4a5KgBiAnRmPg09ufby7dgMPF6b8BWdvathFtjhtE25j--J) [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=)。专家指出，由于甲型H3N2亚型病毒在过去两年未在中国大范围流行，公众对其普遍缺乏免疫基础，这可能导致感染人数增加，且甲型H3N2流感病毒的传染性更强、传播速度更快，常引发肺炎等下呼吸道并发症 [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [bjd](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDKh5ce29Cix9_W-gs3vzboBhfOjZrxzB6RR1Slw0A1gLBXjs3HGox0H7-evqCAtLwr5SfGV1mZMOXZbV_MJtohdwW5DMLcita4etRYPQk5VoAzHb9mcD5YA9PqAO3HEoxELS9n92sXAunG54=)。在受影响人群中，5至14岁年龄组的流感病毒检测阳性率显著高于其他年龄组，尤其3-6岁儿童因在幼儿园和学校交叉感染风险高，就诊人数集中 [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [qq](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKXHKAHQ10ou-5TjNMkoZoR7QK4rv0cyniOvVdkTp-qrpHL5FoqKG2i_nKxBLTr9mhAsqJVsTfR9lJihXTGjWD8i4K5C4O7LpR3A-5DkFLl-noFToJCAYN63F0131A0Q3zn8Bfft8=)。

在此背景下，作为广谱抗流感病毒药物的奥司他韦，其市场需求和销量出现大幅增长。同时，2025年被业界称为“国产流感创新药元年”，多款国产创新抗流感药物的获批上市，正在改变流感药物市场的竞争格局 [chinapress](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKz0yD5U75kXEHbmM1U3RRAZogBdZ_JFdH5JIAhPVeoNKZwllmF34uSXshpn88JwEWrmbq07X02YPDS0WDCGGVFs0YkZ3OkaTTa4zl6WWrFNyqn7gGnZ9WRtsbJnsVJqJ7Dhm6egjc0rQjkxFSCB-_pkqOl_1LmIGazKAosvYHgXIj6L4atZHUhJW8EzRvpfI_mYAylpkRtUNOkc7gvF56NKfgCHeisCx_ssSdc8bvfvGIaxdRvJNCzChfaCvZ3GkuD9EmgtO-KB5UvVBQaXWTPkOrp_Ukfarr87nBNTNBhbPl-4q0eHbkWjhfZ9-KSuj1EHkhseqtNgjR1AGxqtQjwBgyQVQcoh4=) [udn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGXiq6Lak6ieIc6I2tHqBxJwsNeSHLCSYMmvnmZhbxthlQWXMQdo6Q4kyRA3hvob5VgJra8cTWm6zP-1bMB4a5KgBiAnRmPg09ufby7dgMPF6b8BWdvathFtjhtE25j--J) [sina](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF59Mqe_JVGW3LjrAFHM8_lMAd3xdrflszQCFOfl0-s1cYAS4JK8JD0vRg4Bke7-aIUgY6N9EoWx7F20nMTH-Sm7DpqTCdUy8j0i1SWjN2phXxb6ppFQAbH_HJ07YYgbfUQHsCTi4iIgWzqht-xDdWWrsSbm5k_yF8=)。

## 深度分析

### 1. 奥司他韦销量激增的驱动因素
奥司他韦在近期销量显著增长，部分平台近7天上涨237% [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=) [szhk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGU9t8CSX2ikqwrDXr7b_jBMgchcH8glGcq8rZVfZFs_QmBYB0xdV3Emesz5kT9sYQ4iBSy6TPQ0c-MNgBvU9h4z4RaCo5cWWDG5s5hQJMvdyzRb_2vKiFFMAKP2tV7N9lBUp7RVpYn)，主要原因在于：
- **流感疫情提前且强度增加**：2025年中国流感季提前到来，且主要流行的甲型H3N2亚型病毒因公众免疫基础薄弱，导致感染人数增加，特别是儿童群体感染率高，加剧了对流感治疗药物的需求 [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [bjd](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDKh5ce29Cix9_W-gs3vzboBhfOjZrxzB6RR1Slw0A1gLBXjs3HGox0H7-evqCAtLwr5SfGV1mZMOXZbV_MJtohdwW5DMLcita4etRYPQk5VoAzHb9mcD5YA9PqAO3HEoxELS9n92sXAunG54=)。
- **奥司他韦的广泛认知与应用**：作为经典的抗流感病毒药物，奥司他韦在临床上被广泛使用，尤其在儿童流感治疗中占据重要地位，其“可威”品牌在儿科市场占有率超过95% [chinapress](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSusXcvfOaAKJRxCW1I8axDaafmmoji_G0muuXoIzxA0NZPvVWRiWLrsBO7vuO2gwNJgo8h9ooOQs2Vre6wurvRYqLrbs5o0COgyLpM_QPwkchkAg1VbiiX5s01wAumyHkk8JnWhu-PHSRojF0wWk77BwnyoVBoXIEdExa6-3zrRhNLO8RmlPv3rZSLA7K03nRdJ4mU9mPvEN7VRW0_IRMrtAw02EtZd9D0oe2Nnq8V3O4we_5OrDEz6n-1c4whSvmMSYeN7mF2loGHqGhoOEjEXXrb43RYUTY3DGuXAaCVuOA5Hcyoe1rO3Q6GdI1KIBbT9Be3sW-Y4Bm9vbIxy77kWrgMIYkx5nm) [szhk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSkZze7YYoKuBHTyUv-4qorRCHDpfkqoEggAjhUAUbUfRrmpZnDlQmlKxafr-5_2MI0hsgdUtX_UDrwu2Q1y3IMhUQLIf23MyXurmYOkGMFkSrsNXySaOD5MFkBdYCTOmIn3kyZhn9gQ==)。
- **生产企业积极响应市场需求**：为应对激增的需求，奥司他韦生产企业自10月中旬以来已连续7天24小时不间断生产，以保障市场供应 [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=) [udn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGXiq6Lak6ieIc6I2tHqBxJwsNeSHLCSYMmvnmZhbxthlQWXMQdo6Q4kyRA3hvob5VgJra8cTWm6zP-1bMB4a5KgBiAnRmPg09ufby7dgMPF6b8BWdvathFtjhtE25j--J) [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErry8sXUAd_oOkKns0mxl4bB5ocYoRA-CnJi2tNMvsbD3oTsVnxxoBz2-HXabRC0EU636kv0G5F43QN9UdZSLZAgC5xbMaOn0ukQxbrZeX5kPWrHu6zzbDXD86EER_df94YstBgIo=)。

### 2. 市场供应与价格现状
尽管奥司他韦需求旺盛，但市场供应总体充足，价格则在多重因素影响下呈现“内卷”态势：
- **供应保障**：截至2025年11月，多家线上医药平台和线下药店均表示，奥司他韦等药品的储备充足，供应链运转有序，未出现大范围缺货现象 [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=) [udn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGXiq6Lak6ieIc6I2tHqBxJwsNeSHLCSYMmvnmZhbxthlQWXMQdo6Q4kyRA3hvob5VgJra8cTWm6zP-1bMB4a5KgBiAnRmPg09ufby7dgMPF6b8BWdvathFtjhtE25j--J) [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErry8sXUAd_oOkKns0mxl4bB5ocYoRA-CnJi2tNMvsbD3oTsVnxxoBz2-HXabRC0EU636kv0G5F43QN9UdZSLZAgC5xbMaOn0ukQxbrZeX5kPWrHu6zzbDXD86EER_df94YstBgIo=)。
- **价格“内卷”**：国家药品集中带量采购（集采）政策的持续推进，使得奥司他韦仿制药价格大幅下降。奥司他韦胶囊和干混悬剂分别纳入第七、八批全国药品集采，最低中选价降幅达85%，平均降价83%，部分药店仿制药售价甚至低至每粒不足1元 [cna](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXzQFl-6jRkVYISfWKCZDg6Q4Jj32PzuxXO3QqU7X9sZhei3zDnu-gOx13uQq2pukxA0V43uwJzLTz9OKQBC9g97-8c3UrmYk3Z-BuN7fgVXB36XoLisMBCqS56fvitXKzJySY3KADf2JlX7c=) [qq](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKXHKAHQ10ou-5TjNMkoZoR7QK4rv0cyniOvVdkTp-qrpHL5FoqKG2i_nKxBLTr9mhAsqJVsTfR9lJihXTGjWD8i4K5C4O7LpR3A-5DkFLl-noFToJCAYN63F0131A0Q3zn8Bfft8=) [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErry8sXUAd_oOkKns0mxl4bB5ocYoRA-CnJi2tNMvsbD3oTsVnxxoBz2-HXabRC0EU636kv0G5F43QN9UdZSLZAgC5xbMaOn0ukQxbrZeX5kPWrHu6zzbDXD86EER_df94YstBgIo=)。
- **原研药与仿制药价格差异**：尽管仿制药价格低廉，罗氏旗下的原研药达菲（奥司他韦胶囊）在药店标价仍较高，例如75mg*10粒装为191元/盒 [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErry8sXUAd_oOkKns0mxl4bB5ocYoRA-CnJi2tNMvsbD3oTsVnxxoBz2-HXabRC0EU636kv0G5F43QN9UdZSLZAgC5xbMaOn0ukQxbrZeX5kPWrHu6zzbDXD86EER_df94YstBgIo=)。
- **市场规模**：中国抗流感药物市场规模在2023年已超过百亿元，预计到2027年将达到223.9亿元，奥司他韦作为主流用药，其市场需求在流感季的推动下持续旺盛 [163](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFRADl3R6lX7YmasbMBGJ0zwgFEAcD2d2gy7Z012B_Kw1o7lBpQKUo5jsl1gutCMfLqrTCFBSGALRA65b1vxidyCYwTmaB5j69QBzyLycYKbPnZfD6VfITMPAYsPb_XLv5aslV4l8B7FaTPeP-piQ==) [sina](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFd9PZ3GO2WkF280lkKILVGQEGtGtZz1ATHYjE7MeZIKwzRrveL40eSOr-JVgu3pS01HXvBzBVgiQuM4zT9m7dAcD1NYJmddSZxMF6a0KDwTmsKLyCUJBdV8Co0AobIaw6XcAQeeiUbAujr1af1mMQW3s_qBWXvaOM=)。

### 3. 流感药物市场竞争格局变化
2025年被称为“国产流感创新药元年”，多款新型流感药物的上市正在改变传统流感药市场格局：
- **国产创新药密集上市**：
    - **玛舒拉沙韦片（伊速达）**：全球第二个、中国首个自主研发的靶向流感病毒RNA聚合酶PA亚基的抗病毒药物，单次服药，耐药突变率低于1% [sina](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF59Mqe_JVGW3LjrAFHM8_lMAd3xdrflszQCFOfl0-s1cYAS4JK8JD0vRg4Bke7-aIUgY6N9EoWx7F20nMTH-Sm7DpqTCdUy8j0i1SWjN2phXxb6ppFQAbH_HJ07YYgbfUQHsCTi4iIgWzqht-xDdWWrsSbm5k_yF8=) [cnr](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXy_HOTz__Eia_NNgshxIiZORdEZryvh1wmt1jsFIjqrQucWbqsUyfyfEKBd6JCKr1YBiVQuWAH8NjPHp5JUB8vmPfCoBTTRttolPpW2pGtToBIX2KipOhq77pX5rLbXDy7X_1eBW-LhYgGhLknONzQQPrNvJU)。
    - **昂拉地韦片（安睿威）**：全球首个靶向甲型流感病毒RNA聚合酶PB2亚基的抗流感药物，每日一次，连续服用5天，对奥司他韦和玛巴洛沙韦耐药株均有强效抑制作用，耐药性风险较低 [oeeee](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJAMd6N7nwa0GyOsCD2agh5lJgDpM3MSIRHh5uJAblcyhBm62wqSa2hnH80ytTdsJuNk2ikcV5NEBmR7cs_Ns0e3OEYoFjKU13HPi82mGCJTzASsLXghjJXbIusqbVdRD_5_Mff_x8NsQur9YTlPcGBQ==) [xinhuanet](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEft1k5qn6pi6iLWqy6k7kFXx5QdAF5s-MifXl-qT9CX20vQk5jnnBMvwJsMmJdEJiG_QWam6Ne6w-9VzrM8vQw78WA3LE1b5Nuzx3WL5og6XUzw2SXzltbmedqIUA92gutFL43i5VxVINlM6shA5LMKK8UqQ8Bdy2hFZNVACD3mISi8h2_3Q==)。
    - **玛硒洛沙韦片（济可舒）**：我国自主研发的靶向流感病毒RNA聚合酶PA亚基新型抑制剂，单次用药，能显著缩短流感症状缓解时间和病毒RNA转阴时间，耐药位点突变率仅为1.8% [nmpa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFy6_TnWlEmGCdytc_Ntu6bnfFmtCTkwTBoodQoRVXCNGaFzdPCGVa2_0n5Dfz1MXrupAMAUTKuFpKsflMnTxazYbairAQk5ms1mz5wjbIa0Lcqktxja4d1QBzOHQaj92z60zTdtNuWwYGIFEs86MYcjrmVrXhWFS45HWP5GvkhEZIaPL8dBDGP9A==) [gmw](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEf332ZRa4mIiRENK5YfyRXs6Nm-xKFbqANuDbnTun1E7NYaVO4T74tX9CpQgLb7nRQPLEzhy6OuiztotCYn72uV6HElCGpi_7mzh2zs3J3nNX445lTLEVI3hsi4mgKzM3BtFMPHefUF2l88g==)。
- **与奥司他韦和玛巴洛沙韦的竞争**：
    - **奥司他韦**：尽管面临新药竞争和集采降价，奥司他韦仍是中国抗流感药物市场的主导者，市场占有率超过70%，尤其在儿童用药领域具有不可替代的地位 [chinapress](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKz0yD5U75kXEHbmM1U3RRAZogBdZ_JFdH5JIAhPVeoNKZwllmF34uSXshpn88JwEWrmbq07X02YPDS0WDCGGVFs0YkZ3OkaTTa4zl6WWrFNyqn7gGnZ9WRtsbJnsVJqJ7Dhm6egjc0rQjkxFSCB-_pkqOl_1LmIGazKAosvYHgXIj6L4atZHUhJW8EzRvpfI_mYAylpkRtUNOkc7gvF56NKfgCHeisCx_ssSdc8bvfvGIaxdRvJNCzChfaCvZ3GkuD9EmgtO-KB5UvVBQaXWTPkOrp_Ukfarr87nBNTNBhbPl-4q0eHbkWjhfZ9-KSuj1EHkhseqtNgjR1AGxqtQjwBgyQVQcoh4=) [udn](https://udn.com/news/story/7332/7592990) [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErry8sXUAd_oOkKns0mxl4bB5ocYoRA-CnJi2tNMvsbD3oTsVnxxoBz2-HXabRC0EU636kv0G5F43QN9UdZSLZAgC5xbMaOn0ukQxbrZeX5kPWrHu6zzbDXD86EER_df94YstBgIo=)。
    - **玛巴洛沙韦（速福达）**：罗氏公司推出的创新药，凭借单次用药的便利性迅速打开市场，但存在耐药性和不良反应方面的担忧，在成人/青少年群体中耐药突变检出率约为10%，儿童试验中可超20% [raynovent](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGUrItNT0ubtZS0WQdCmJu2QsBYJJYPmGDKZtPorEKazEuQEoywcPekVTxnvCuYIsifZezp0xmpYeYSiWEIx_5fT6k7m1UrzjSdswGCCkAHMLeK6ZymaKVmSKJDSx_nVgTVd6V)。
    - **新药优势**：国产创新药凭借单次用药的便捷性、更早抑制病毒复制的机制以及在耐药性方面的优势，有望提供更具竞争力的价格，提高药物可及性，打破进口药物单一的市场格局 [bccmedianews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELwVd3uuoV-Lv5T8ofCmtHPv30xJnFWgCp-36mops9xC309Gb2f5MobDaaoVZDoaXOqKKae4Yp5D9b5eGaYmFc3PO86qB2NuULK_zqIJLbUb7IUb4IgV-RX6Q=)。

## 结论与建议

### 结论
- 2025年11月，中国流感疫情提前且强度增加，导致奥司他韦销量在短期内显著增长，反映了公众对流感治疗药物的迫切需求。
- 尽管需求旺盛，奥司他韦的市场供应总体充足，且在国家集中采购政策的推动下，仿制药价格趋于合理，提高了药物的可及性。
- 2025年国产流感创新药的密集上市，预示着中国流感药物市场正从奥司他韦和玛巴洛沙韦的“二人转”转向多方竞争的局面，但奥司他韦凭借其广泛的临床应用和在儿童用药领域的优势，仍将是市场的重要基石。

### 建议
- **对公众**：
    - **及时接种流感疫苗**：这是预防流感最有效的方式，世界卫生组织已公布2025-2026年北半球流感季节推荐的疫苗病毒成分 [cna](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXzQFl-6jRkVYISfWKCZDg6Q4Jj32PzuxXO3QqU7X9sZhei3zDnu-gOx13uQq2pukxA0V43uwJzLTz9OKQBC9g97-8c3UrmYk3Z-BuN7fgVXB36XoLisMBCqS56fvitXKzJySY3KADf2JlX7c=) [chinapress](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE4rAwEqeyZmgpAVNmP2Hx8PckJrhu6EszpD2oeIipZm3yhJRTqrRU3TSHb3q8bHigqyz7XPpAZ-1wSFGtb6urugbzBOBxqBZ0osEgOj8pz5xe9ecGfBXV2WNeVRMFuqxB0oZ5LuZfdQZA7qhhnXdRNoPJrQizIKmUtkRfek-EI4Le3rTVm4xZRFN1FEkFm-uo-MZPWJPTo83TPOKmglUYLgGpF9l733_tird7yVHa00mjC0UrgJiwl2PIdY-oHhwEAN-TaC9uU6cGBTKa078-MjPkOO27lSAS45ZcO836K8ym0ljD0A3dLEpbyMB-NWdtjyo6LaijJa6aQo3sUF0OaU3xsTJ-YNERs)。
    - **保持良好个人卫生习惯**：勤洗手、戴口罩、注意呼吸道卫生和咳嗽礼仪、保持居室通风换气等 [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [qq](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKXHKAHQ10ou-5TjNMkoZoR7QK4rv0cyniOvVdkTp-qrpHL5FoqKG2i_nKxBLTr9mhAsqJVsTfR9lJihXTGjWD8i4K5C4O7LpR3A-5DkFLl-noFToJCAYN63F0131A0Q3zn8Bfft8=)。
    - **出现症状及时就医**：特别是高热、全身酸痛和乏力等流感样症状，应及时就医，并在医生指导下合理用药 [qq](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKXHKAHQ10ou-5TjNMkoZoR7QK4rv0cyniOvVdkTp-qrpHL5FoqKG2i_nKxBLTr9mhAsqJVsTfR9lJihXTGjWD8i4K5C4O7LpR3A-5DkFLl-noFToJCAYN63F0131A0Q3zn8Bfft8=)。
- **对医疗机构和学校**：
    - **加强健康监测**：对流感样病例进行登记和管理，及时发现和报告聚集性疫情 [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [qq](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKXHKAHQ10ou-5TjNMkoZoR7QK4rv0cyniOvVdkTp-qrpHL5FoqKG2i_nKxBLTr9mhAsqJVsTfR9lJihXTGjWD8i4K5C4O7LpR3A-5DkFLl-noFToJCAYN63F0131A0Q3zn8Bfft8=)。
    - **做好环境清洁和通风**：保持室内空气流通，减少病毒传播风险 [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [qq](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKXHKAHQ10ou-5TjNMkoZoR7QK4rv0cyniOvVdkTp-qrpHL5FoqKG2i_nKxBLTr9mhAsqJVsTfR9lJihXTGjWD8i4K5C4O7LpR3A-5DkFLl-noFToJCAYN63F0131A0Q3zn8Bfft8=)。
    - **落实带病不带岗/课制度**：建议学生和教职员工带病不带岗、不带课，避免疾病传播 [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=) [qq](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKXHKAHQ10ou-5TjNMkoZoR7QK4rv0cyniOvVdkTp-qrpHL5FoqKG2i_nKxBLTr9mhAsqJVsTfR9lJihXTGjWD8i4K5C4O7LpR3A-5DkFLl-noFToJCAYN63F0131A0Q3zn8Bfft8=)。
- **对医药企业和监管部门**：
    - **持续保障药物供应**：确保奥司他韦及其他抗流感药物的稳定生产和供应，以应对疫情高峰 [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=) [udn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGXiq6Lak6ieIc6I2tHqBxJwsNeSHLCSYMmvnmZhbxthlQWXMQdo6Q4kyRA3hvob5VgJra8cTWm6zP-1bMB4a5KgBiAnRmPg09ufby7dgMPF6b8BWdvathFtjhtE25j--J)。
    - **关注创新药市场表现**：密切监测新上市国产创新药的市场份额、临床应用效果及耐药性变化，推动其合理定价和医保纳入，以提升药物可及性 [bccmedianews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELwVd3uuoV-Lv5T8ofCmtHPv30xJnFWgCp-36mops9xC309Gb2f5MobDaaoVZDoaXOqKKae4Yp5D9b5eGaYmFc3PO86qB2NuULK_zqIJLbUb7IUb4IgV-RX6Q=)。

### 限制条件与待后续验证的问题
- 新上市国产创新药的长期市场份额和销售额数据尚待公布，其能否成功纳入国家医保目录以及商业化推广策略将是决定其市场竞争力的关键。
- 流感病毒的持续变异可能对现有药物的疗效产生影响，需要持续监测和研究。
- 公众对新型流感药物的认知度和接受度，以及其在真实世界中的应用效果，仍需进一步观察和验证。

## 数据与引用
- [shaoxing](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwm9_baUxpOOShrf_q1qAEfbU4FHtfszHj7VWEaHTc0u-dG7T67vp4rpftUlhPnyWdN07fb-XkYlDBBBEPp3O3D7qDOzsK0ZIPjROPvjv5s3ijaRs1FUVa0yBlEfFpqSPsw90=)
- [szhk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGU9t8CSX2ikqwrDXr7b_jBMgchcH8glGcq8rZVfZFs_QmBYB0xdV3Emesz5kT9sYQ4iBSy6TPQ0c-MNgBvU9h4z4RaCo5cWWDG5s5hQJMvdyzRb_2vKiFFMAKP2tV7N9lBUp7RVpYn)
- [udn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGXiq6Lak6ieIc6I2tHqBxJwsNeSHLCSYMmvnmZhbxthlQWXMQdo6Q4kyRA3hvob5VgJra8cTWm6zP-1bMB4a5KgBiAnRmPg09ufby7dgMPF6b8BWdvathFtjhtE25j--J)
- [chinapress](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKz0yD5U75kXEHbmM1U3RRAZogBdZ_JFdH5JIAhPVeoNKZwllmF34uSXshpn88JwEWrmbq07X02YPDS0WDCGGVFs0YkZ3OkaTTa4zl6WWrFNyqn7gGnZ9WRtsbJnsVJqJ7Dhm6egjc0rQjkxFSCB-_pkqOl_1LmIGazKAosvYHgXIj6L4atZHUhJW8EzRvpfI_mYAylpkRtUNOkc7gvF56NKfgCHeisCx_ssSdc8bvfvGIaxdRvJNCzChfaCvZ3GkuD9EmgtO-KB5UvVBQaXWTPkOrp_Ukfarr87nBNTNBhbPl-4q0eHbkWjhfZ9-KSuj1EHkhseqtNgjR1AGxqtQjwBgyQVQcoh4=)
- [sina](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFd9PZ3GO2WkF280lkKILVGQEGtGtZz1ATHYjE7MeZIKwzRrveL40eSOr-JVgu3pS01HXvBzBVgiQuM4zT9m7dAcD1NYJmddSZxMF6a0KDwTmsKLyCUJBdV8Co0AobIaw6XcAQeeiUbAujr1af1mMQW3s_qBWXvaOM=)
- [163](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFRADl3R6lX7YmasbMBGJ0zwgFEAcD2d2gy7Z012B_Kw1o7lBpQKUo5jsl1gutCMfLqrTCFBSGALRA65b1vxidyCYwTmaB5j69QBzyLycYKbPnZfD6VfITMPAYsPb_XLv5aslV4l8B7FaTPeP-piQ==)
- [jiemian](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQYb3dE7HMbUXaw3dZ_pzyB-GL2N3KyZA8ntOduILanP4os3RBQtoE_0OsSVPIWbl3bRv7PynZ-pg0vGBHhh70MOzJUd22dd7pHLYLaZHEx5ck9JvJWgl6bkjZCzqaHVlxoQr7Nvg=)
- [bjd](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDKh5ce29Cix9_W-gs3vzboBhfOjZrxzB6RR1Slw0A1gLBXjs3HGox0H7-evqCAtLwr5SfGV1mZMOXZbV_MJtohdwW5DMLcita4etRYPQk5VoAzHb9mcD5YA9PqAO3HEoxELS9n92sXAunG54=)
- [people](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFRQ0ySItgn4ljgI5TkhJIQNJfmF9_KACy9mLSZcVYL8u7Wcez2DUhXpXS4qIT0AmBLV47KiB4npMue0vE6vR-MmCNe-KWyiI-ke0wlw3Af2yGhYtZUvhNR2ONuTzDFMBYoQSvqC3zikz6c4jVwIH0WUUs7VTkf1ac=)
- [qq](https://vertexaisearch.google.com/id/1-4)
- [cna](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXzQFl-6jRkVYISfWKCZDg6Q4Jj32PzuxXO3QqU7X9sZhei3zDnu-gOx13uQq2pukxA0V43uwJzLTz9OKQBC9g97-8c3UrmYk3Z-BuN7fgVXB36XoLisMBCqS56fvitXKzJySY3KADf2JlX7c=)
- [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa2ryq2zmiV6hPPlqyLQp73qvBIl_k7sOxY0Loj1ddmVSawG5J4fwKAobf-H0xIXgyKd5C271k9Rf7DlDH_13jSaCf7Jl1X9rZGksznIsdULpQosHSR627xwSPlfis4rJ-1VtYrVw=)
- [chinapress](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE4rAwEqeyZmgpAVNmP2Hx8PckJrhu6EszpD2oeIipZm3yhJRTqrRU3TSHb3q8bHigqyz7XPpAZ-1wSFGtb6urugbzBOBxqBZ0osEgOj8pz5xe9ecGfBXV2WNeVRMFuqxB0oZ5LuZfdQZA7qhhnXdRNoPJrQizIKmUtkRfek-EI4Le3rTVm4xZRFN1FEkFm-uo-MZPWJPTo83TPOKmglUYLgGpF9l733_tird7yVHa00mjC0UrgJiwl2PIdY-oHhwEAN-TaC9uU6cGBTKa078-MjPkOO27lSAS45ZcO836K8ym0ljD0A3dLEpbyMB-NWdtjyo6LaijJa6aQo3sUF0OaU3xsTJ-YNERs)
- [cfi](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErry8sXUAd_oOkKns0mxl4bB5ocYoRA-CnJi2tNMvsbD3oTsVnxxoBz2-HXabRC0EU636kv0G5F43QN9UdZSLZAgC5xbMaOn0ukQxbrZeX5kPWrHu6zzbDXD86EER_df94YstBgIo=)
- [sina](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUB-m7srVt9-jc5QxZ5BWrGG66aK2EatQTN8VDwUFZj6eTgqyp7nTVwcaHKkEhrQnq94nqijql7nAGVXeVFg7Q4CF2KA4cQRzSFzVAGG8C8BConMWS__AJoBSGq42GQdqvLKF1f_sprkG8o8z9wWG6adevizYx-6Q=)
- [chinapress](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSusXcvfOaAKJRxCW1I8axDaafmmoji_G0muuXoIzxA0NZPvVWRiWLrsBO7vuO2gwNJgo8h9ooOQs2Vre6wurvRYqLrbs5o0COgyLpM_QPwkchkAg1VbiiX5s01wAumyHkk8JnWhu-PHSRojF0wWk77BwnyoVBoXIEdExa6-3zrRhNLO8RmlPv3rZSLA7K03nRdJ4mU9mPvEN7VRW0_IRMrtAw02EtZd9D0oe2Nnq8V3O4we_5OrDEz6n-1c4whSvmMSYeN7mF2loGHqGhoOEjEXXrb43RYUTY3DGuXAaCVuOA5Hcyoe1rO3Q6GdI1KIBbT9Be3sW-Y4Bm9vbIxy77kWrgMIYkx5nm)
- [szhk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSkZze7YYoKuBHTyUv-4qorRCHDpfkqoEggAjhUAUbUfRrmpZnDlQmlKxafr-5_2MI0hsgdUtX_UDrwu2Q1y3IMhUQLIf23MyXurmYOkGMFkSrsNXySaOD5MFkBdYCTOmIn3kyZhn9gQ==)
- [sina](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF59Mqe_JVGW3LjrAFHM8_lMAd3xdrflszQCFOfl0-s1cYAS4JK8JD0vRg4Bke7-aIUgY6N9EoWx7F20nMTH-Sm7DpqTCdUy8j0i1SWjN2phXxb6ppFQAbH_HJ07YYgbfUQHsCTi4iIgWzqht-xDdWWrsSbm5k_yF8=)
- [cnr](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXy_HOTz__Eia_NNgshxIiZORdEZryvh1wmt1jsFIjqrQucWbqsUyfyfEKBd6JCKr1YBiVQuWAH8NjPHp5JUB8vmPfCoBTTRttolPpW2pGtToBIX2KipOhq77pX5rLbXDy7X_1eBW-LhYgGhLknONzQQPrNvJU)
- [dfcfw](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG2uouSCX2FZg6CcJXO-yNi6wYGwlNW_pR6Y2FwO6g_3_MY2T_mIfj7mD5ElAVJcvT-4i_ejfAnUUFA1LYvLRcDRTMOkSOiZDUe1eUaTZPRpvrYiu6a01OBlVyPdBCjozshoF_aoFBa9nhLUNPOkcHIp_6Nc4tQnhGkcDPJmzGM_KX9PA==)
- [oeeee](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJAMd6N7nwa0GyOsCD2agh5lJgDpM3MSIRHh5uJAblcyhBm62wqSa2hnH80ytTdsJuNk2ikcV5NEBmR7cs_Ns0e3OEYoFjKU13HPi82mGCJTzASsLXghjJXbIusqbVdRD_5_Mff_x8NsQur9YTlPcGBQ==)
- [xinhuanet](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEft1k5qn6pi6iLWqy6k7kFXx5QdAF5s-MifXl-qT9CX20vQk5jnnBMvwJsMmJdEJiG_QWam6Ne6w-9VzrM8vQw78WA3LE1b5Nuzx3WL5og6XUzw2SXzltbmedqIUA92gutFL43i5VxVINlM6shA5LMKK8UqQ8Bdy2hFZNVACD3mISi8h2_3Q==)
- [nmpa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFy6_TnWlEmGCdytc_Ntu6bnfFmtCTkwTBoodQoRVXCNGaFzdPCGVa2_0n5Dfz1MXrupAMAUTKuFpKsflMnTxazYbairAQk5ms1mz5wjbIa0Lcqktxja4d1QBzOHQaj92z60zTdtNuWwYGIFEs86MYcjrmVrXhWFS45HWP5GvkhEZIaPL8dBDGP9A==)
- [gmw](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEf332ZRa4mIiRENK5YfyRXs6Nm-xKFbqANuDbnTun1E7NYaVO4T74tX9CpQgLb7nRQPLEzhy6OuiztotCYn72uV6HElCGpi_7mzh2zs3J3nNX445lTLEVI3hsi4mgKzM3BtFMPHefUF2l88g==)
- [raynovent](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGUrItNT0ubtZS0WQdCmJu2QsBYJJYPmGDKZtPorEKazEuQEoywcPekVTxnvCuYIsifZezp0xmpYeYSiWEIx_5fT6k7m1UrzjSdswGCCkAHMLeK6ZymaKVmSKJDSx_nVgTVd6V)
- [bccmedianews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELwVd3uuoV-Lv5T8ofCmtHPv30xJnFWgCp-36mops9xC309Gb2f5MobDaaoVZDoaXOqKKae4Yp5D9b5eGaYmFc3PO86qB2NuULK_zqIJLbUb7IUb4IgV-RX6Q=)